Methods of Nucleoside Synthesis. Vorbrueggen, Helmut. Res. Lab., Schering A.-G., Berlin, D-1000/65, Fed. Rep. Ger. NATO Adv. Study Inst. Ser., Ser. A (1979), A26(Nucleoside Analogues: Chem., Biol., Med. Appl.), 35-69. |
Vorbruggen et al., "Nucleoside Synthesis with Trimethylsilyl Triflate and Perchlorate as Catalysts," Chem. Ber. 114, pp. 1234-1255 (1981). |
Vorbruggen et al., "New Catalysts for the Synthesis of Nucleosides," Angew. Chem. Internat. Edit. 14(6), pp. 421-422 (1974). |
Gordon et al., "Kinetics of Decay in the Expression of Interferon-Dependent mRNAs Responsible for Resistance to Virus," Proc. Nat. Acad. Sci. USA 77(1), 452-456 (Jan. 1980). |
Devivar et al., "Benzimidazole Ribonucleosides: Observation of An Unexpected Nitration WHen Performing Non-Aqueous Diazotizations with t-butyl Nitrite," Biorganic & Medicinal Chem. Letters, 2(9), 1105-1110 (Sep. 1992). |
Tigges et al., "Human CD8+ Herpes Simplex Virus-Specific Cytotoxic T-Lymphocyte Clones Recognize Diverse Viron Protein Antigens," J. Virology, 66(3), 1622-1634 (Mar. 1992). |
Devivar et al., "Benzimidazole Ribonucleosides: Design, Synthesis, and Antiviral Activity of Certain 2-(Alkylthio)-and 2-(benzylthio)-5,6-dichloro-1-(.beta.-D-ribofuranosyl)benzimidazoles," J. Medicinal Chem., 37(18), 2942-2949 (Sep. 2, 1994). |
Townsend et al.(VII), "Design Synthesis, and Antiviral Activity of Certain 2,5,6-Trihalo-1-(.beta.-D-ribofuranosyl)benzimidazoles," J. Medicinal Chem., 38(20), 4098-4105 (Sep. 25, 1995). |
Yankulov et al., "The Transcriptional Elongation Inhibitor 5-6-Dichloro-1-.beta.-D-ribofuransylbenzimidazole Inhibits Translation Factor IIH-Associated Protein Kinase," J. Biol Chem., 270(41), 23922-23925 (Oct. 13, 1995). |
Nassiri et al., "Comparison of Benzimidazole Nucleosides and Ganciclovir on the In Vitro Prol;iferation and Colony Formation of Human Bone Marrow Progenitor Cells," British J. Haematology, 93(2), 273-279 (May 1996). |
Gudmundsson et al., "Synthesis and Antiviral Activity of Certain 5'-Modified Analogs of 2,5,6-Trichloro-1-(.beta.-D-ribofuranosyl)benzimidazole," J. Medicinal Chem., 40(5), 785-793 (Feb. 28, 1997). |
Zou et al., "Design, Synthesis, and Antiviral Evaluation of 2-Chloro-5,6-dihalo-1-(.beta.-D-ribofuranosyl)benzimidazoles as Potential Agents for Human Cytomegalovirus Infections," J. Medicinal Chem., 40(5), 811-818 (Feb. 28, 1997). |
Physician's Desk Reference, 52nd Ed., Arky and Sifton (eds.), Medical Economics Co., Montvale, NJ, 1998. only pp. 2452-2454 supplied (see "Cytovene"). Month of publication date is unavailable. |
The Merck Index, 11th Ed., Budavari et al. (eds.), Merck & Co., Rahway, NJ, 1989, only p. 682 supplied. Month of publication date is unavailable. |
Revankar, G.R. et al., The Synthesis of 2-Chloro-1-(.beta.-D-ribofuranosyl)benzimidazole and Certain Related Derivatives (1), J. Heterocycles, vol. 5, pp. 477-483, 1968 (Aug.). |
Revankar, G.R. et al., The Synthesis of 2-Chloro-1-.beta.-D-ribofuranosyl-5,6-dimethylbenzimidazole and Certain Related Derivatives (1), J. Heterocycles, vol. 5, No. 4, pp. 615-620, 1968. (Oct.) |
European Patent Office Search Report (Apr. 26, 1996; ref. no. 1263W 94). |
European Patent Office Communication (Aug. 6, 1997; ref. no. PB1548/EPw). |
Gosselin et al., "Synthesis and biological evaluation of new 5,6-dichlorobenzimidazole nucleoside derivatives", Antiviral Chem. Chemotherapy, vol. 5, pp. 243-256, (1994) (Issue No. 4). |